Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application
- PMID: 12791824
Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application
Abstract
99mTc-hydrazinonicotinamido (HYNIC)-annexin V is a novel tracer for in vivo imaging of apoptosis. The present study on humans was performed to investigate the safety of (99m)Tc-HYNIC-annexin V and to quantify the biodistribution and radiation dose.
Methods: Six healthy, male volunteers participated in the study. A dual-head gamma camera was used to acquire conjugate anterior and posterior views. Imaging started with a transmission scan using a (57)Co-flood source to obtain a map of the local thickness of the volunteer. Approximately 250 MBq of (99m)Tc-HYNIC-annexin V were injected intravenously, directly followed by a 30-min dynamic study. Whole-body scans were obtained at about 30 min, 3 h, 6 h, and 24 h after injection. Organ uptake was determined after correction for background, scatter, and attenuation. The MIRDOSE3.1 program was used to calculate organ-absorbed doses and effective dose. Signs of adverse effects were investigated by monitoring renal and liver function, hematology, blood coagulation, and vital signs (blood pressure, pulse, respiration rate, temperature, and electrocardiogram).
Results: The kidneys accumulated 49.7 +/- 8.1 percentage injected dose (%ID) at 3 h after injection; the liver, 13.1 +/- 1.0 %ID; the red marrow, 9.2 +/- 1.8 %ID; and the spleen, 4.6 +/- 1.6 %ID. More than 90% of the blood activity was cleared with a half-life of 24 +/- 3 min. The biologic half-life of the activity registered over the total body was long (69 +/- 7 h). Excretion of the activity was almost exclusively through the urine (22.5 +/- 3.5 %ID at 24 h), and hardly any activity was seen in the bowel or feces. Absorbed doses were found to be 196 +/- 31 micro Gy/MBq for the kidneys, 41 +/- 12 micro Gy/MBq for the spleen, 16.9 +/- 1.3 micro Gy/MBq for the liver, and 8.4 +/- 0.9 micro Gy/MBq for the red marrow. The effective dose was 11.0 +/- 0.8 micro Sv/MBq, or 2.8 +/- 0.2 mSv for the average injected activity of 250 MBq. No adverse effects were observed.
Conclusion: (99m)Tc-HYNIC-annexin V is a safe radiopharmaceutical, having a favorable biodistribution for imaging of apoptosis in the abdominal as well as thoracic area with an acceptable radiation dose.
Similar articles
-
Patient dosimetry of intravenously administered 99mTc-annexin V.J Nucl Med. 2001 Feb;42(2):382-7. J Nucl Med. 2001. PMID: 11216539
-
Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans.Nucl Med Commun. 2003 Aug;24(8):871-80. doi: 10.1097/01.mnm.0000084585.29433.58. Nucl Med Commun. 2003. PMID: 12869819 Clinical Trial.
-
Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans.Eur J Nucl Med. 2001 Sep;28(9):1373-8. Eur J Nucl Med. 2001. PMID: 11585297
-
Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors.Semin Nucl Med. 2010 Jul;40(4):220-41. doi: 10.1053/j.semnuclmed.2010.02.004. Semin Nucl Med. 2010. PMID: 20513446 Review.
-
Apoptosis-detecting radioligands: current state of the art and future perspectives.Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):887-919. doi: 10.1007/s00259-004-1555-4. Epub 2004 May 12. Eur J Nucl Med Mol Imaging. 2004. PMID: 15138718 Review.
Cited by
-
Preliminary biological evaluation of novel (99m)Tc-Cys-annexin A5 as a apoptosis imaging agent.Molecules. 2013 Jun 10;18(6):6908-18. doi: 10.3390/molecules18066908. Molecules. 2013. PMID: 23752473 Free PMC article.
-
Preliminary biological evaluation of ¹⁸F-FBEM-Cys-Annexin V a novel apoptosis imaging agent.Molecules. 2015 Mar 17;20(3):4902-14. doi: 10.3390/molecules20034902. Molecules. 2015. PMID: 25789822 Free PMC article.
-
In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer [(18)F]-CP18 for PET imaging of apoptosis in tumors.Mol Imaging Biol. 2013 Dec;15(6):748-57. doi: 10.1007/s11307-013-0646-7. Mol Imaging Biol. 2013. PMID: 23689985
-
Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis.Mol Imaging Biol. 2015 Dec;17(6):838-47. doi: 10.1007/s11307-015-0852-6. Mol Imaging Biol. 2015. PMID: 25896815 Free PMC article.
-
Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V.Proc Am Thorac Soc. 2009 Aug 15;6(5):469-76. doi: 10.1513/pats.200901-001AW. Proc Am Thorac Soc. 2009. PMID: 19687221 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources